Cerus Corporation · NASDAQ:CERS
Cerus — Investor Presentation (September 2025)
27 slides from Cerus's investor presentation, September 2025
Slide 1: Cerus Corporation
Cerus Corporation September 2025 Not to be Reproduced
Slide 2: Forward Looking Statements
Forward Looking Statements Except for the historical statements contained herein, this presentation contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ 2025 annual product revenue guidance and key milestones for 202
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures This presentation includes certain financial information presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including adjusted EBITDA and the percentage growth in EMEA product revenue, excluding the impac
Slide 4: Cerus: Focused on Safeguarding the Blood Supply
Cerus: Focused on Safeguarding the Blood Supply To make the INTERCEPT® Blood System the Our Mission standard of care for transfused blood components Pathogen Inactivation/Reduction Market Leader with ~20 years in the market Our Reach Global sales in >40 countries Cumulative kit sales for > 20 millio
Slide 5: Why CERS?
Why CERS? • Market leader in pathogen reduction technologies for transfused blood components • First mover advantage; superior technology and significant barriers to entry for competition • Repeat orders from longstanding and growing customer base contributes to recurring revenues • Concentrated blo
Slide 6: Cerus' Current Products and Development Pipeline
Cerus’ Current Products and Development Pipeline INTERCEPT Blood Systems Early Development Registration Studies Regulatory Commercially Available Commercially available in the U.S. Commercially available in Europe1 Platelets Commercially available in Latin America2 Joint venture with Shandong Zhongb
Slide 7: Large & Growing Global Addressable Market Opportunity for INTERCEPT
Large & Growing Global Addressable Market Opportunity* for INTERCEPT Addressable Markets for $5.0B Worldwide Platelet Market Commercially Available INTERCEPT Products $1.3B Potential TAM Growth Today 5-7 Years $0.7B Global $1.3 B >$1.5 B U.S. $150 MM >$200 MM $200 MM to $300MM $203 MM Cerus 2025 Fib
Slide 8: 2024 Product Revenue and Revised 2025 Product Revenue Guidance
2024 Product Revenue and Revised 2025 Product Revenue Guidance * $200-203* Revised 2025 product revenue guidance range: $200 million to $203 million* Includes 2025 IFC∞ revenue guidance range: $16 million to $18 million* *2025 Product revenue guidance updated by Cerus on and as of August 5, 2025. Pr
Slide 9: The Unmet Need: Proactive Protection of the Blood Supply and Ensuring Availability
The Unmet Need: Proactive Protection of the Blood Supply and Ensuring Availability Not to be Reproduced
Slide 10: Why the Blood Supply?
Why the Blood Supply? Blood Transfusion is a Common and Critical Supportive Therapy Used for Many Types of Patients >100 million units of blood are donated per year worldwide DONOR BLOOD CENTER HOSPITAL PATIENT A single donation of whole blood can be used to make four major blood components: PLATELE
Slide 11: Emerging Pathogens: Is Testing a Sustainable Solution?
Emerging Pathogens: Is Testing a Sustainable Solution? Development time, cost, continual emergence of new pathogens 30 years of testing = protection against 11 agents HIV, Hepatitis B, Hepatitis C, HTLV, bacteria, West Nile virus, T. Cruzi, Syphilis, Babesiosis, Zika, Leukocytes Zika Babesiosis Cost
Slide 12: Treatment Process - INTERCEPT Blood System for Platelets and Plasma
Treatment Process - INTERCEPT Blood System for Platelets and Plasma 2 Inactivate* INT200 UVA Illuminator* (A similar treatment set is used for platelets.) *INT200 displayed in the images. CE Mark approved in the EU. Not approved for commercial sale in the U.S. 12 Not to be Reproduced
Slide 13: INTERCEPT Blood System for Platelets & Plasma Pathogen Reduction System
INTERCEPT® Blood System for Platelets & Plasma Pathogen Reduction System INTERCEPT crosslinks DNA and RNA Enveloped viruses to prevent pathogen replication Non-enveloped Potential Pathogens INTERCEPT viruses in Donated Platelet Platelet component Gram-negative Donor Patient bacteria Gram-positive ba
Slide 14: INT200 - Next Generation LED Based Illumination Device
INT200 - Next Generation LED Based Illumination Device • Intuitive Design, Simplified Handling • Touch Screen Navigation, Intuitive Software • Improved Tray Design • Intelligent Scanning • Custom Reporting • Compact Design • Streamlined for a Faster Workflow • Received early approvals 1H 2025 • CE M
Slide 15: Be Ready. When Minutes Matter
Be Ready. When Minutes Matter ® Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex, IFC) produced from the Not to be Reproduced INTERCEPT® Blood System for Cryoprecipitation MKT-EN 00472-02, v9.0 *INTERCEPT Fibrinogen Complex is available for immediate use for up to
Slide 16: Hemorrhage is a Leading Cause of Preventable Death
Hemorrhage is a Leading Cause of Preventable Death1 #1 ~40% 1.6 Cause Hours Trauma is the #1 cause of death Of these, ~40% are The median time to death from in adults <45 years old2 the result of bleeding2 exsanguination* is 1.6 hours3,4 Trauma5,6 Cardiac (CV) Surgery7 Postpartum Hemorrhage8 Combat9
Slide 17: What is INTERCEPT Fibrinogen Complex (IFC)?
What is INTERCEPT® Fibrinogen Complex (IFC)? • INTERCEPT® Fibrinogen Complex is a pathogen reduced blood component for fibrinogen supplementation • Approved to treat and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency • Immediate*, enriched source of key fact
Slide 18: Shorter Turnaround Times (TAT) & Minimized Wastage
Shorter Turnaround Times (TAT) & Minimized Wastage IFC accelerates availability, minimizes wait times and increases reliability and predictability of blood component delivery. Barnes-Jewish 1 2 3 4 C Hospital 40 min 10 min Order to Issue IFC reduces blood component wastage, improving blood stewardsh
Slide 19: INTERCEPT Red Blood Cells Development Program
INTERCEPT Red Blood Cells Development Program* * INTERCEPT Red Blood Cells are in development and are not currently licensed for sale in any geography. Not to be Reproduced
Slide 20: INTERCEPT RBC Clinical Development Program
INTERCEPT RBC Clinical Development Program1 Successfully Completed Ongoing In Vitro Characterization Recovery & Lifespan In Vitro Characterization Recovery and Survival (Grifols Sets)(n=65) (n=26) (Grifols Sets) (Fenwal Sets)(n=65) (Fenwal Sets)(n=24) Report in Progress Completed Report in Progress
Slide 21: Q2:25 Financial Results and Highlights
Q2:25 Financial Results and Highlights 21 Not to be Reproduced
Slide 22: Continued Commercial, Developmental, and Operational Execution
Continued Commercial, Developmental, and Operational Execution ✓ Record quarterly results led by increasing IFC sales Raising 2025 full year product & IFC revenue guidance EU regulatory review of INTERCEPT RBC ongoing DoD amendment supports funding of CRYO-FIRST Focused to achieve non-GAAP adjusted
Slide 23: Second Quarter Results Reflect Strong Start to 2025
Second Quarter Results Reflect Strong Start to 2025 Quarterly Product Revenue Product Revenue • Q2:25 product revenue of $52.4 million, +16% year-over-year (Y/Y) • North American product revenue growth of 17% Y/Y millions • EMEA reported product revenue 21% Y/Y; non-GAAP, excluding Fx, product reven
Slide 24: Fifth Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA
Fifth Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA ‡ $ millions Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Net Loss Attributable to Cerus Corporation (9.7) (5.8) (2.9) (2.5) (7.7) (5.7) Adjustments to Net Loss Attributable to Cerus Corporation Income Tax Provision (Benefit) 0.1 (0.1) 0.1 0.1 0.
Slide 25: Quarterly Cash and Operating Cash Flow Trends
Quarterly Cash* and Operating Cash Flow Trends Cash flow from operations Cash, cash equivalents, & ($ Millions) short-term investments ($ Millions) Cash, cash equivalents, & short-term investments Cash flow from operations Striving to deliver second straight year of positive operating cash flows 25
Slide 26: Where Do We Go From Here?
Where Do We Go From Here? Future Expansion of INTERCEPT’s Global Reach INTERCEPT Blood System for Platelets & Plasma Extend leadership Anticipated expansion into Development of in current markets new markets (e.g., China) next-generation products INTERCEPT Fibrinogen Complex Generation of real-world
Slide 27: Cerus Corporation
Cerus Corporation Investor Relations IR@cerus.com (925) 288-6137 Not to be Reproduced